Skip to content

Does the Optic Disc Grading Done Visually by Your Doctor Agree With Optic Nerve Testing Which is Done by Machines?

Correlation of DDLS Grading to OCT, HRT, and HVF

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00430287
Enrollment
101
Registered
2007-02-01
Start date
2007-03-31
Completion date
2008-10-31
Last updated
2016-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open Angle Glaucoma

Keywords

primary open angle glaucoma, low tension glaucoma, pigmentary glaucoma, exfoliative glaucoma

Brief summary

The purpose of this study is to determine how well the DDLS (Disc Damage Likelihood Scale) (which is a method used by the eye doctor to evaluate how healthy the optic nerve is) measures up to the standard glaucoma tests: OCT (Optical Coherence Tomography), the HRT (Heidelberg Retinal Tomography) and the HVF (Humphrey Visual Field).

Detailed description

The Disc Damage Likelihood Scale (DDLS) has been shown to be a reproducible method for clinicians to evaluate the optic nerve for glaucomatous damage and is highly correlated to diagnosis of glaucoma, severity of glaucoma as evidenced by visual field loss and Heidelberg Retina Tomography (HRT) evaluation. In comparison with the commonly used cup-disc ratio, the DDLS has less inter-observer variation and captures glaucomatous aspects of the optic nerve not assessed by the cup-disc ratio. The optic nerve imagers do not have the potential to completely replace the clinical examination of the optic nerve since they do not assess many critical features such as optic nerve pallor, hemorrhages, asymmetry of disc size, edema, etc. The DDLS presents the opportunity to provide a system to clinicians to increase the quality and objectivity of clinical optic nerve evaluation. The purpose of this study is to investigate the correlation of the DDLS grading to OCT, HRT and HVF testing of glaucomatous and normal optic nerves.

Interventions

None listed

Sponsors

Merck Sharp & Dohme LLC
CollaboratorINDUSTRY
Wills Eye
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
45 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Vision 20/50 or better * Less than 3 diopters of astigmatism * 3 diopters or less of myopia or hyperopia * Pattern Standard Deviation on HVF less than 2.5dB in normals * Pattern Standard Deviation on HVF greater than 2.5 db in glaucoma patients

Exclusion criteria

* Abnormalities of cornea or ocular media * Significant ocular pathologies affecting visual field * History of hypotony * Ocular surgery within 6 months * Nystagmus * Unreliable visual fields * OCT signal strength scan less than 6

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026